Trojano M, Avolio C, Ruggieri M, De Robertis F, Giuliani F, Paolicelli D, Livrea P
Institute of Clinical Neurology, University of Bari, Italy.
Mult Scler. 1998 Feb;4(1):39-44. doi: 10.1177/135245859800400110.
Serum and cerebrospinal fluid (CSF) soluble intercellular adhesion molecule-I (ICAM-I) levels were evaluated (ELISA) in 22 untreated and 13 corticosteroid-treated active relapsing remitting (RR) Multiple Sclerosis (MS), in 10 untreated and 10 corticosteroid-treated Guillain-Barré syndrome (GBS) and in 17 non-inflammatory neurological diseases (NIND). Twenty-eight clinically inactive RR MS were assayed for serum sICAM-I before and after 3 months treatment of 8 MIU rIFN beta-Ib taken s.c. every other day. High sICAM-I serum levels above the NIND values were found in untreated clinically active MS and in untreated GBS (P < 0.05) but not in the untreated clinically inactive MS group. The active MS group showed significantly (P = 0.0001) higher sICAM-I serum levels if compared to the inactive group. Corticosteroid-treated active MS and GBS patients showed lower (P < 0.05) serum sICAM-I levels than the corresponding untreated groups. Serum sICAM-I levels after 3 months of rIFN beta-Ib treatment (P < 0.0001, paired t-test) resulted increased compared to pretreatment values in MS. The mean values of CSF/serum sICAM-I:CSF/serum Albumin ratios (sICAM-I Index) in active untreated MS patients were higher compared to NIND (P < 0.005) and to corticosteroid-treated MS group (P = 0.01). sICAM Index values in GBS did not differ from those in NIND. The results seem to suggest potential roles for serum sICAM-I in downregulating the ongoing inflammatory response at the blood-brain barrier level and for CSF sICAM-I in the maintenance of a central nervous system local immune response.
采用酶联免疫吸附测定法（ELISA）评估了22例未经治疗以及13例接受皮质类固醇治疗的活动性复发缓解型（RR）多发性硬化症（MS）患者的血清和脑脊液（CSF）可溶性细胞间黏附分子-1（ICAM-1）水平，还评估了10例未经治疗以及10例接受皮质类固醇治疗的吉兰-巴雷综合征（GBS）患者以及17例非炎性神经系统疾病（NIND）患者的上述指标。对28例临床非活动性RR MS患者，在皮下隔日注射8 MIU重组干扰素β-1b进行3个月治疗前后检测血清可溶性ICAM-1（sICAM-1）水平。在未经治疗的临床活动性MS患者和未经治疗的GBS患者中发现血清sICAM-1水平高于NIND组（P<0.05），但在未经治疗的临床非活动性MS组中未发现此现象。与非活动性组相比，活动性MS组的血清sICAM-1水平显著更高（P = 0.0001）。接受皮质类固醇治疗的活动性MS和GBS患者的血清sICAM-1水平低于相应的未经治疗组（P<0.05）。在MS患者中，重组干扰素β-1b治疗3个月后的血清sICAM-1水平与治疗前相比有所升高（P<0.0001，配对t检验）。未经治疗的活动性MS患者脑脊液/血清sICAM-1:脑脊液/血清白蛋白比值（sICAM-1指数）的平均值高于NIND组（P<0.005）以及接受皮质类固醇治疗的MS组（P = 0.01）。GBS患者的sICAM指数值与NIND组无差异。结果似乎表明血清sICAM-1在下调血脑屏障水平的持续炎症反应中可能发挥作用，而脑脊液sICAM-1在维持中枢神经系统局部免疫反应中可能发挥作用。
